Table 2.
Outcomes after HFNC therapy, HFNC, high-flow nasal cannula.
| Total (n = 15) | HFNC success (n = 8) | HFNC failure (n = 7) | |
|---|---|---|---|
| Baseline | |||
| HR (bpm), median (IQR) | 94 (72–97) | 84 (73.3–94.5) | 97 (82–107) |
| RR (/min), median (IQR) | 24 (21.5–30.5) | 28.5 (22.5–32.8) | 22 (21.5–24) |
| SpO2/FiO2, median (IQR) | 131.4 (118.1–153.9) | 135.7 (130–172.4) | 116.3 (115.6–128.6) |
| 2 – 6 h after HFNC | |||
| HR (bpm), median (IQR) | 74 (68.5–90) | 73 (69.3–79) | 76 (65.5–91.5) |
| RR (/min), median (IQR) | 24 (21–24.5) | 23 (21.5–24) | 25 (22–26) |
| SpO2/FiO2, median (IQR) | 188 (140.8–225.1) | 203.9 (174.1–247.9) | 180 (130.3–191) |
HFNC, high-flow nasal cannula; IQR, interquartile range; HR, heart rate; RR, respiratory rate; SpO2, saturation of percutaneous oxygen; FiO2, fraction of inspired oxygen.